XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2023
Summary of Disaggregation of Revenues

The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):

 

 

 

Year Ended

 

 

Year Ended

 

 

Year Ended

 

 

December 31, 2023

 

 

December 31, 2022

 

 

December 31, 2021

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

Product revenue, net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HEPLISAV-B

 

$

213,295

 

 

$

-

 

 

$

213,295

 

 

$

124,996

 

 

$

941

 

 

$

125,937

 

 

$

61,870

 

 

$

-

 

 

$

61,870

 

CpG 1018 adjuvant

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

587,708

 

 

 

587,708

 

 

 

-

 

 

 

375,229

 

 

 

375,229

 

Total product revenue, net

 

$

213,295

 

 

$

-

 

 

$

213,295

 

 

$

124,996

 

 

$

588,649

 

 

$

713,645

 

 

$

61,870

 

 

$

375,229

 

 

$

437,099

 

Other revenue

 

 

17,650

 

 

 

1,339

 

 

 

18,989

 

 

 

8,774

 

 

 

264

 

 

 

9,038

 

 

 

1,915

 

 

 

428

 

 

 

2,343

 

Total revenues

 

$

230,945

 

 

$

1,339

 

 

$

232,284

 

 

$

133,770

 

 

$

588,913

 

 

$

722,683

 

 

$

63,785

 

 

$

375,657

 

 

$

439,442

 

HEPLISAV-B  
Schedule of Revenues from Major Customers

The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):

 

 

 

Year Ended

 

 

December 31,

 

 

2023

 

 

2022

 

 

2021

 

Largest customer

 

 

28

%

 

 

21

%

 

 

21

%

Second largest customer

 

 

27

%

 

 

17

%

 

 

19

%

Third largest customer

 

 

17

%

 

 

16

%

 

 

19

%

Summary of Product Revenue Allowance and Reserve Categories

The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories (in thousands):

 

 

 

Balance at
Beginning of
Period

 

 

Provisions
related to current
period sales

 

 

Credit or payments
made during
the period

 

 

Adjustments related to prior periods

 

 

Balance
at End of
Period

 

Year ended December 31, 2023:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable reserves (1)

 

$

8,179

 

 

$

55,604

 

 

$

(54,143

)

 

$

(2,629

)

 

$

7,011

 

Revenue reserve accruals (2)

 

$

10,552

 

 

$

46,062

 

 

$

(38,207

)

 

$

2,597

 

 

$

21,004

 

Year ended December 31, 2022:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable reserves (1)

 

$

3,823

 

 

$

34,758

 

 

$

(30,402

)

 

$

-

 

 

$

8,179

 

Revenue reserve accruals (2)

 

$

8,253

 

 

$

24,806

 

 

$

(22,507

)

 

$

-

 

 

$

10,552

 

(1) Reserves are for chargebacks, discounts and other fees.

(2) Accruals are for returns, rebates and other fees.

CpG 1018  
Schedule of Revenues from Major Customers

The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant product revenue):

 

 

 

Year Ended

 

 

December 31,

 

 

2023

 

 

2022

 

 

2021

 

Largest collaboration partner

 

 

0

%

 

 

49

%

 

 

49

%

Second largest collaboration partner

 

 

0

%

 

 

35

%

 

 

24

%

Third largest collaboration partner

 

 

0

%

 

 

12

%

 

 

19

%

 

Summary of balances and activities in our contract asset account The following table summarizes balances and activities in our contract asset account (in thousands):

 

 

 

Balance at
Beginning
of Period

 

 

Additions

 

 

Subtractions

 

 

Reclassification (1)

 

 

Balance
at End of
Period

 

Year ended December 31, 2023:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contract asset, included in other current assets (2)

 

$

71,965

 

 

$

17,650

 

 

$

(16,919

)

 

$

(71,307

)

 

$

1,389

 

Contract asset, included in other assets (long term)

 

$

-

 

 

$

-

 

 

$

-

 

 

$

71,307

 

 

$

71,307

 

Year ended December 31, 2022:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contract asset

 

$

62,525

 

 

$

17,556

 

 

$

(8,116

)

 

$

-

 

 

$

71,965

 

(1) The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 9 for further discussion.

(2) The $1.4 million of contract asset is derived from our agreement with the DoD.